Targeting RNase L to human immunodeficiency virus RNA with 2-5A- antisense

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 3, 1998, Pages 225-231

  Player, M R ^a   Maitra, R K ^b   Silverman, R H ^c   Torrence, P F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Angiography Core Laboratory   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

2 5A; AIDS; Human immunodeficiency virus; Oligonucleotides; RNA degradation; RNA secondary structure; RNase L

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; RIBONUCLEASE; VIRUS RNA;

ARTICLE; CHIMERA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA CLEAVAGE; RNA DEGRADATION; RNA STRUCTURE; SCREENING;

EID: 0031746651     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900303     Document Type: Article

References (37)

1. Boiziau C, Kurfurst R, Cazenave C, Roig V, Thuong NT & Toulme J-J (1988) Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Research 16:3341-3358.
2. Cagnon L, Cucchiarini M, Lefebvre J-C & Doglio A (1995) Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 9:349-358.
3. Chastin M & Tinoco I Jr (1993) RNA structure as related to antisense drugs. In Antisense Research and Applications, pp. 55-66. Edited by ST Crooke & B Lebleu. Boca Raton: CRC Press.
4. Cirino NM, Li G, Xiao W, Torrence PF & Silverman RH (1997) Targeting RNA for decay in respiratory syncytial virus infected cells with 2″5′ oligoadenylate antisense. Proceedings of the National Academy of Sciences, USA 94:1937-1942.
5. Dash P, Lotan I, Knapp M, Kandel ER & Goelet P (1987) Selective elimination of mRNA in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proceedings of the National Academy of Sciences, USA 84:7896-7900.
6. De Clercq E (1995a) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews 8:200-209.
7. De Clercq E (1995b) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38:2491-2517.
8. Ecker DJ (1993) Strategies for invasion of RNA secondary structure. In Antisense Research and Applications, pp. 387-400. Edited by ST Crooke & B Lebleu. Boca Raton: CRC Press.
9. Freier S (1993) Hybridization: considerations affecting antisense drugs. In Antisense Research and Applications, pp. 67-82. Edited by ST Crooke & B Lebleu. Boca Raton: CRC Press.
10. Homann M, Tzortzakaki S, Rittner K, Sczakiel G & Tabler M (1993) Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Research 21:2809-2814.
11. Jencks WP (1969) Catalysis in Chemistry and Enzymology, pp. 1-41. New York: McGraw-Hill.
12. Kin S-G, Suzuki Y, Nakashima H, Yamamoto N & Takaku H (1991) Phosphorothioate analogues of oligodeoxyribonucleotides: synthesis and activity as inhibitors of replication of human immunodeficiency virus. Biochemical and Biophysical Research Communications 179:1614-1619.
13. Kinchington D, Galpin S, Jaroszewski JW, Ghosh K, Subasinghe C &. Cohen JS (1992) A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Research 17:53-62.
14. Lesiak K, Khamnei S & Torrence PF (1993) 2′,5′-Oligoadenylate: antisense chimeras - synthesis and properties. Bioconjugate Chemistry 4:467-472.
15. Li G, Xiao W & Torrence PF (1997) Synthesis and properties of second generation 2-5A-antisense chimeras with enhanced resistance to exonucleases. Journal of Medicinal Chemistry 40:2959-2966.
16. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P & Gallo RC (1992) Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proceedings of the National Academy of Sciences, USA 89:11209-11213.
17. Lisziewicz J, Sun D, Metelev V, Zamecnik P, Gallo RC & Agrawal S (1993) Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proceedings of the National Academy of Sciences, USA 90:3860-3864.
18. Lund OS, Nielsen JO & Hansen J-E (1995) Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev. Antiviral Research 28:81-91.
19. Maitra RK, Li G, Xiao W, Dong B, Torrence PF & Silverman RH (1995) Catalytic cleavage of an RNA target by 2-5A antisense and RNase L. Journal of Biological Chemistry 270:15071-15705.
20. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence PF & Silverman RH (1994) Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265:789-792.
21. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS & Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 84:7706-7710.
22. Mori K, Subasinghe C & Cohen JS (1989) Oligodeoxynucleotide analogs with 5′-linked anthraquinone. FEBS Letters 249:213-218.
23. Milligan JF, Mateucci MD & Martin JC (1993) Current concepts in antisense drug design. Journal of Medicinal Chemistry 36:1923-1937.
24. Rayner B, Matsukara M, Morvan F, Cohen JS & Imbach J-L (1989) In vitro anti-HIV activity of phosphorothioate α-anomeric oligodeoxynucleotides. CR Acad Sci III 310:61-64.
25. Sarin PS, Agrawal S, Civeira MP, Goodchild J, Ikeuchi T & Zamecnik PC (1988) Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proceedings of the National Academy of Sciences, USA 85:7448-7451.
26. Sczakiel G, Pawlita M & Kleinheinz A (1990) Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5′-leader/gag region. Biochemical and Biophysical Research Communications 169:643-651.
27. Shibahara S, Mukai S, Morisawa H, Nakashima H, Kobayashi S & Yamamoto N (1989) Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives. Nucleic Acids Research 17:239-252.
28. Silverman RH & Krause D (1987) Analysis of antiviral mechanisms: interferon regulated 2′,5′-oligoadenylate and protein kinase systems. In Lymphokines and Interferons: A Practical Approach, pp. 149-193. Edited by MJ Clemens, AG Morris and AJH Gearing. Oxford: IRL Press.
29. Stephenson ML & Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA 75:285-288.
30. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A & Silverman RH (1993) Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proceedings of the National Academy of Sciences, USA 90:1300-1304.
31. Torrence PF, Xiao W, Li G, Lesiak K, Khamnei S, Maran A, Maitra R, Dong B & Silverman RH (1994) 2′,5′-Oligoadenylate antisense chimeras for targeted ablation of RNA. In Carbohydrate Modifications in Antisense Research, pp. 119-132. Edited by YS Sanghvi & PD Cook. Washington DC: American Chemical Society.
32. Torrence PF, Xiao W, Li G, Cramer H, Player MR & Silverman RH (1997) Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Development 7:203-206.
33. Xiao W, Li G, Lesiak K, Dong B, Silverman RH & Torrence PF (1994) Synthesis of a 5′-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease. Bioorganic and Medicinal Chemistry Letters 4:2609-2614.
34. Xiao W, Player MR, Li G, Zhang K, Lesiak K & Torrence PF (1996) Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antisense Research and Development 6:247-258.
35. Zamecnik PC & Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences, USA 75:280-284.
36. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S & Diasio RB (1995) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM91) in HIV-infected subjects. Clinical Pharmacology and Therapeutics 58:44-53.
37. Zuker M (1989) Computer predicition of RNA structure. Methods in Enzymology 180:262-288.